<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365593">
  <stage>Registered</stage>
  <submitdate>9/01/2014</submitdate>
  <approvaldate>9/01/2014</approvaldate>
  <actrnumber>ACTRN12614000029695</actrnumber>
  <trial_identification>
    <studytitle>A feasibility study of Panax ginseng therapy for moderate to very severe chronic obstructive pulmonary disease </studytitle>
    <scientifictitle>A randomised controlled feasibility study of Panax ginseng therapy versus placebo on the rate of exacerbation in moderate to very severe chronic obstructive pulmonary disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NA</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic obstructive pulmonary disease</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Alternative and Complementary Medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral Panax ginseng extract, G115, in capsule form, 200 mg per day for 4 weeks. The participants will be asked to complete a daily diary to note down when they take the study medications. Drug tablet return will also be checked at every visit to improve adherence.</interventions>
    <comparator>Oral lactose based Placebo 20200 mg per day for 4 weeks</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Rate of exacerbation
This will be assessed as the unmber of exacerbations based on on the pre defined definition. That is, change in baseline dyspnoea, cough and/or sputum, specifically two or more symptoms such as worsening dyspnoea, increase sputum purulence, volume or both, or any single major symptom plus more than one minor symptom including upper airway infection, unexpected fever, or increased wheezing that lasts 2 or more days</outcome>
      <timepoint>10 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>St Georges Respiratory Questionnaire (SGRQ)</outcome>
      <timepoint>10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>COPD Assessment Test (CAT)</outcome>
      <timepoint>10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Short-form Health survey (SF-36) </outcome>
      <timepoint>10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>6-minute walking test (6MWT)</outcome>
      <timepoint>10 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. aged between 40 and 80 years 2. postbronchodilator forced expiratory volume in 1 second (FEV1) equal to 20% and less than 80% of predicted normal values and FEV1 to forced vital capacity (FVC) of less than 70% 3. clinically stable, not have experienced an acute exacerbation of COPD from at least 4 weeks prior to trial entry and not to have been hospitalised in the past 6 months with greater than or equal to 3 exacerbations 4. meet the Chinese medicine diagnostic criteria for Lung Qi deficiency with or without Spleen or Kidney Qi deficiency. </inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. history of asthma or chronic systemic infections or inflammatory conditions other than COPD that require systemic corticosteroid treatment in the last 3 months 2. pregnant, breast-feeding or intending to become pregnant during the course of the study 3. have serious illnesses such as severe heart, liver or kidney disease 4. taking long-term immunosuppressive agents or immune-stimulants; allergic history to ginseng or currently taking ginseng; users of monoamine oxidase inhibitor antidepressants, anticoagulants and/or anti-hyperglycaemic medications 5. and those who had undertaken pulmonary rehabilitation within 3 months of the commencement of the study or intend to enter pulmonary rehabilitation during the study. </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Opaque envelopes containing a number concealed to the treatment allocation was used to randomly assign subjects. Medications, in packages concealed to the randomisation code were dispensed from the hospitals central pharmacy by blinded pharmacists.</concealment>
    <sequence>A computer generated randomisation list was supplied by an independent bio statistician. </sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Analysis of all outcomes will be by t-test at the end of each time point. Data will be evaluated with an intention-to-treat method using Last Observation Carried Forward (LOCF). A sample size calculation was not performed as this is a feasability to study to gauage the applicability of implmenting a larger sale trial. A sample size of 10 was selected by the investigators. </statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/08/2012</anticipatedstartdate>
    <actualstartdate>1/08/2012</actualstartdate>
    <anticipatedenddate>1/10/2012</anticipatedenddate>
    <actualenddate>1/10/2012</actualenddate>
    <samplesize>20</samplesize>
    <actualsamplesize>20</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>China</country>
      <state>Guangzhou</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>RMIT University</primarysponsorname>
    <primarysponsoraddress>PO Box 71, Bundoora, Victoria, 3083 Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC) </fundingname>
      <fundingaddress>GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Guangdong Provincial Academy of Chinese Medical Sciences</fundingname>
      <fundingaddress>111 Dade Rd, Guangzhou, Guangdong, China</fundingaddress>
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Guangdong Provincial Academy of Chinese Medical Sciences</sponsorname>
      <sponsoraddress>111 Dade Rd, Guangzhou, Guangdong, China</sponsoraddress>
      <sponsorcountry>China</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a feasibility study to evaluate a trial protocol for Panax ginseng versus placebo in patients with moderate to very severe chronic obstructive pulmonary disease.</summary>
    <trialwebsite>NA</trialwebsite>
    <publication>Wu L, Zhang AL, Di YM, Shergis JL, et al. Panax ginseng therapy for chronic obstructive pulmonary disease: a clinical trial protocol and pilot study. Chinese medicine. 2014: 9:20.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Guangdong Provincial Hospital Human Ethics Committee</ethicname>
      <ethicaddress>111 Dade Rd, Guangzhou, Guangdong, China</ethicaddress>
      <ethicapprovaldate>6/06/2012</ethicapprovaldate>
      <hrec>B2012-49-01</hrec>
      <ethicsubmitdate />
      <ethiccountry>China</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Charlie Xue</name>
      <address>RMIT University, PO BOX 71, Bundoora, 3083 VIC</address>
      <phone>+61 3 9925 7360</phone>
      <fax />
      <email>charlie.xue@rmit.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Johannah Shergis</name>
      <address>RMIT University, PO BOX 71, Bundoora, 3083 VIC</address>
      <phone>+61 3 9925 6527</phone>
      <fax />
      <email>johannah.shergis@rmit.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Johannah Shergis</name>
      <address>RMIT University, PO BOX 71, Bundoora, 3083 VIC</address>
      <phone>+61 3 9925 6527</phone>
      <fax />
      <email>johannah.shergis@rmit.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Johannah Shergis</name>
      <address>RMIT University, PO BOX 71, Bundoora, 3083 VIC</address>
      <phone>+61 3 9925 6527</phone>
      <fax />
      <email>johannah.shergis@rmit.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>